Comparative Pharmacology
Head-to-head clinical analysis: PAZOPANIB HYDROCHLORIDE versus QLOSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAZOPANIB HYDROCHLORIDE versus QLOSI.
PAZOPANIB HYDROCHLORIDE vs QLOSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pazopanib is a multi-targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors (VEGFR-1, -2, -3), platelet-derived growth factor receptors (PDGFR-α, -β), and stem cell factor receptor (c-Kit). It also inhibits other kinases such as fibroblast growth factor receptors (FGFR-1, -3), cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor (c-Fms).
QLOSI is a monoclonal antibody that binds to and inhibits the activity of interleukin-5 (IL-5), thereby reducing eosinophil production and survival.
800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). Do not crush tablets.
100 mg orally once daily.
None Documented
None Documented
Terminal half-life is approximately 31 hours, supporting once-daily dosing.
Terminal elimination half-life is approximately 9 hours; clinical context: allows twice-daily dosing in patients with normal renal function.
Primarily fecal (83%), with renal elimination accounting for <4% of the administered dose.
Primarily renal excretion of unchanged drug (approximately 85%), with the remainder eliminated via biliary/fecal routes (15%).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor